Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Plus Therapeutics (PSTV) EBT Margin (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed EBT Margin for 15 consecutive years, with 417.92% as the latest value for Q4 2025.

  • Quarterly EBT Margin fell 14151.0% to 417.92% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 301.75% through Dec 2025, down 5104.0% year-over-year, with the annual reading at 301.75% for FY2025, 5104.0% down from the prior year.
  • EBT Margin for Q4 2025 was 417.92% at Plus Therapeutics, down from 316.61% in the prior quarter.
  • The five-year high for EBT Margin was 1606.03% in Q3 2021, with the low at 7186.3% in Q3 2022.
  • Average EBT Margin over 5 years is 664.84%, with a median of 276.42% recorded in 2024.
  • The sharpest move saw EBT Margin plummeted -879234bps in 2022, then surged 711314bps in 2023.
  • Over 5 years, EBT Margin stood at 1606.03% in 2021, then plummeted by -375bps to 4417.32% in 2022, then skyrocketed by 93bps to 290.18% in 2023, then rose by 5bps to 276.42% in 2024, then crashed by -51bps to 417.92% in 2025.
  • According to Business Quant data, EBT Margin over the past three periods came in at 417.92%, 316.61%, and 108.71% for Q4 2025, Q3 2025, and Q2 2025 respectively.